Stock Fundamentals

Company Information

Company Name
Septerna, Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US81734D1046
Currency: USD
Full Time Employees: 130
Phone: 650 338 3533
Fiscal Year End: December
IPO Date: Oct 25, 2024
Description:

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Address:

250 East Grand Avenue, South San Francisco, CA, United States, 94080

Directors & Officers

Name Title Year Born
Dr. Jeffrey T. Finer M.D., Ph.D. Co-Founder, CEO & Director 1967
Ms. Elizabeth P. Bhatt M.B.A., M.S. President & COO 1968
Mr. Gilbert M. Labrucherie C.F.A., J.D. Chief Financial Officer 1972
Dr. Robert J. Lefkowitz M.D. Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board 1944
Dr. Arthur Christopoulos BPHARM, Ph.D. Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board NA
Dr. Patrick Sexton Ph.D. Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board NA
Mr. Richard Hansen Ph.D. Vice President of Technology NA
Mr. Mark A. Wilson J.D. Chief Legal Officer 1972
Mr. George Xu Ph.D. Senior Director of Corporate Development & Portfolio Strategy NA
Ms. Samira Shaikhly Chief People Officer 1970

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 15, 2026 Elizabeth Bhatt N/A Sale 4.00K $24.34 $97.36K
Mar 02, 2026 Samira Shaikhly N/A Sale 70.45K $28.10 $1.98M
Feb 18, 2026 Elizabeth Bhatt N/A Sale 4.00K $28.97 $115.88K
Nov 10, 2025 Daniel D Long N/A Sale 3.50K $18.06 $63.23K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 7.00M Mar 31, 2026 15.52% $1.78 0.00%
TRV GP V, LLC 6.22M Mar 31, 2026 13.79% $37.25 0.00%
Driehaus Capital Management LLC 4.40M Mar 31, 2026 9.75% $0.78 -8.61%
TRV GP VI, LLC 4.21M Mar 31, 2026 9.34% $74.64 0.00%
Samsara BioCapital, LLC 3.15M Mar 31, 2026 6.99% $7.35 0.00%
The Goldman Sachs Group Inc 2.91M Mar 31, 2026 6.45% $0.01 7.05%
Siren, L.L.C. 2.00M Mar 31, 2026 4.44% $1.33 0.00%
BlackRock Inc 1.82M Mar 31, 2026 4.04% $0.00 1.16%
Vanguard Group Inc 1.51M Dec 31, 2025 3.35% $0.00 -0.70%
Bvf Inc 1.35M Mar 31, 2026 3.00% $1.04 -21.36%
venBio Select Advisor LLC 1.34M Mar 31, 2026 2.97% $0.32 0.00%
Vanguard Capital Management, LLC 1.20M Mar 31, 2026 2.66% $0.00 0.00%
ADAR1 Capital Management LLC 1.09M Mar 31, 2026 2.42% $1.54 -5.86%
PRIMECAP Management Company 1.05M Mar 31, 2026 2.33% $0.02 92.06%
HHG PLC 890.75K Mar 31, 2026 1.98% $0.01 0.00%
First Light Asset Management, LLC 732.86K Mar 31, 2026 1.63% $1.58 18.05%
Geode Capital Management, LLC 645.15K Mar 31, 2026 1.43% $0.00 12.64%
State Street Corp 631.45K Mar 31, 2026 1.40% $0.00 16.93%
Casdin Capital, LLC 553.27K Mar 31, 2026 1.23% $1.01 0.00%
VR Adviser, LLC 506.06K Mar 31, 2026 1.12% $0.45 -17.15%

Shares Statistics

Shares Outstanding: 45.08M
Shares Float: 23.12M
% Insiders: 317.50%
% Institutions: 10,263.50%
Short % Float: 11.47%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 906.67K 2.01% ▲ 0.00% Apr 30, 2026
2 PRIMECAP Odyssey Aggressive Growth 749.68K 1.66% ▲ 75.45% Mar 31, 2026
3 iShares Russell 2000 ETF 509.19K 1.13% ▲ 0.93% May 29, 2026
4 Heptagon Driehaus US Micro Cap Eq C$ Acc 406.22K 0.90% ▲ 1.98% Apr 30, 2026
5 Driehaus Small Cap Growth Institutional 394.94K 0.88% ▲ 4.75% Apr 30, 2026
6 Heptagon Driehaus US Sm Cp Eq C USD Acc 363.25K 0.81% ▲ 0.55% Apr 30, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 260.63K 0.58% ▲ 0.54% Apr 30, 2026
8 Fidelity Small Cap Index 210.04K 0.47% ▲ 0.31% Mar 31, 2026
9 iShares Biotechnology ETF 199.55K 0.44% ▲ 1.95% May 29, 2026
10 iShares Russell 2000 Value ETF 184.43K 0.41% ▲ 0.00% May 29, 2026

Valuation Metrics

Enterprise Value: $1.30B
Trailing P/E: 0.00
Forward P/E: 107.53

Financial Highlights

Market Cap: $1.62B
EBITDA: $-66.56M
Book Value: $8.52
Earnings/Share: $-0.80
Profit Margin: -49.88%
Operating Margin: -50.15%
ROA (TTM): -8.49%
ROE (TTM): -9.26%
Revenue (TTM): $72.26M
Revenue/Share (TTM): $1.63
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 12,011.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 4.73x 0.01x 0.36x N/A -0.05x
2024-12-31 27.77x 0.00x 0.08x N/A -0.03x
2023-12-31 16.30x 0.00x 1.29x N/A 0.00x
2022-12-31 5.75x -0.02x 2.22x N/A -0.03x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SEPN.US!